炎症性肠病期间SARS-CoV-2杂交免疫缺陷。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2025-02-01 DOI:10.1016/j.clim.2024.110404

Amin Alirezaylavasani , Ingrid Marie Egner , Børresdatter Dahl , Adity Chopra , Taissa de Matos Kasahara , Guro Løvik Goll , Jørgen Jahnsen , Gunnveig Grødeland , John Torgils Vaage , Fridtjof Lund-Johansen , Jan Cato Holter , Bente Halvorsen , Kristin Kaasen Jørgensen , Ludvig A. Munthe , Hassen Kared

{"title":"炎症性肠病期间SARS-CoV-2杂交免疫缺陷。","authors":"Amin Alirezaylavasani , Ingrid Marie Egner , Børresdatter Dahl , Adity Chopra , Taissa de Matos Kasahara , Guro Løvik Goll , Jørgen Jahnsen , Gunnveig Grødeland , John Torgils Vaage , Fridtjof Lund-Johansen , Jan Cato Holter , Bente Halvorsen , Kristin Kaasen Jørgensen , Ludvig A. Munthe , Hassen Kared","doi":"10.1016/j.clim.2024.110404","DOIUrl":null,"url":null,"abstract":"<div><div>Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for optimizing vaccine strategies in this population.</div><div>While the prevalence of high serological responders post- third COVID-19 vaccine dose was lower, and the antibody waning was higher in IBD patients than in healthy donors (HD), IBD patients showed an increase in anti-RBD Wild Type IgG levels and cross-reactive Spike -specific memory B cells following BTI. However, there was no significant enhancement in cellular immune responses against anti-SARS-CoV-2 post-BTI, with responses instead characterized by activation of SARS-CoV-2 specific and also bystander CD8 T cells. These results suggest a complex interaction between chronic inflammation in IBD and the generation of new immune responses, highlighting the need for tailored vaccine regimens and anti-inflammatory therapies to boost cellular immunity against SARS-CoV-2.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"271 ","pages":"Article 110404"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease\",\"authors\":\"Amin Alirezaylavasani , Ingrid Marie Egner , Børresdatter Dahl , Adity Chopra , Taissa de Matos Kasahara , Guro Løvik Goll , Jørgen Jahnsen , Gunnveig Grødeland , John Torgils Vaage , Fridtjof Lund-Johansen , Jan Cato Holter , Bente Halvorsen , Kristin Kaasen Jørgensen , Ludvig A. Munthe , Hassen Kared\",\"doi\":\"10.1016/j.clim.2024.110404\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for optimizing vaccine strategies in this population.</div><div>While the prevalence of high serological responders post- third COVID-19 vaccine dose was lower, and the antibody waning was higher in IBD patients than in healthy donors (HD), IBD patients showed an increase in anti-RBD Wild Type IgG levels and cross-reactive Spike -specific memory B cells following BTI. However, there was no significant enhancement in cellular immune responses against anti-SARS-CoV-2 post-BTI, with responses instead characterized by activation of SARS-CoV-2 specific and also bystander CD8 T cells. These results suggest a complex interaction between chronic inflammation in IBD and the generation of new immune responses, highlighting the need for tailored vaccine regimens and anti-inflammatory therapies to boost cellular immunity against SARS-CoV-2.</div></div>\",\"PeriodicalId\":10392,\"journal\":{\"name\":\"Clinical immunology\",\"volume\":\"271 \",\"pages\":\"Article 110404\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521661624005138\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521661624005138","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

接受免疫抑制治疗的炎症性肠病（IBD）患者对严重的COVID-19的易感性增加。深入了解SARS-CoV-2疫苗接种和突破性感染（BTI）后的全身炎症和细胞免疫反应，是优化该人群疫苗策略的必要条件。虽然第三次接种COVID-19疫苗后高血清学应答者的患病率较低，并且IBD患者的抗体减弱率高于健康供者（HD），但BTI后IBD患者的抗rbd野生型IgG水平和交叉反应性Spike特异性记忆B细胞升高。然而，bti后抗SARS-CoV-2的细胞免疫反应没有显著增强，而是以激活SARS-CoV-2特异性和旁观者CD8 T细胞为特征。这些结果表明，IBD中的慢性炎症与新免疫反应的产生之间存在复杂的相互作用，强调需要定制疫苗方案和抗炎疗法来增强对SARS-CoV-2的细胞免疫。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

查看原文本刊更多论文

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for optimizing vaccine strategies in this population.

While the prevalence of high serological responders post- third COVID-19 vaccine dose was lower, and the antibody waning was higher in IBD patients than in healthy donors (HD), IBD patients showed an increase in anti-RBD Wild Type IgG levels and cross-reactive Spike -specific memory B cells following BTI. However, there was no significant enhancement in cellular immune responses against anti-SARS-CoV-2 post-BTI, with responses instead characterized by activation of SARS-CoV-2 specific and also bystander CD8 T cells. These results suggest a complex interaction between chronic inflammation in IBD and the generation of new immune responses, highlighting the need for tailored vaccine regimens and anti-inflammatory therapies to boost cellular immunity against SARS-CoV-2.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.